In vitro susceptibility of Candida isolates from organ transplant recipients to newer antifungals.

about

In vitro susceptibility of Candida isolates from organ transplant recipients to newer antifungals.

Item

http://www.wikidata.org/entity/Q42221406

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

In vitro susceptibility of Can ...... cipients to newer antifungals.

@en

In vitro susceptibility of Can ...... cipients to newer antifungals.

@nl

type

Item

label

In vitro susceptibility of Can ...... cipients to newer antifungals.

@en

In vitro susceptibility of Can ...... cipients to newer antifungals.

@nl

prefLabel

In vitro susceptibility of Can ...... cipients to newer antifungals.

@en

In vitro susceptibility of Can ...... cipients to newer antifungals.

@nl

P1476

In vitro susceptibility of Can ...... ecipients to newer antifungals

@en

P2093

Alexandra Geusau

http://www.w3.org/2001/XMLSchema#string

Birgit Willinger

http://www.w3.org/2001/XMLSchema#string

Christine Poitschek

http://www.w3.org/2001/XMLSchema#string

Elisabeth Presterl

http://www.w3.org/2001/XMLSchema#string

P2860

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality

Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents.

Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011.

Infection in organ-transplant recipients.

Anidulafungin versus fluconazole for invasive candidiasis.

Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.

Emerging fungal diseases.

Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations

Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogr

Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).

P2888

s11046-014-9738-4

P304

143-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11046-014-9738-4

http://www.w3.org/2001/XMLSchema#string

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P50

Lukasz Antoniewicz

P577

2014-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24682600

http://www.w3.org/2001/XMLSchema#string